Better lung cancer treatments for Latino and Asian patients
Characterizing treatment responses for common lung cancer (LC) subtypes in Latinos and Asians
This project aims to find better ways to treat lung cancer in Latino and Asian patients by understanding why current treatments sometimes stop working.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11168897 on NIH RePORTER |
What this research studies
This project focuses on a specific type of lung cancer, called EGFR-mutant non-small cell lung cancer, which is more common in Asian American, Native Hawaiian, Pacific Islander, and Latino communities. We want to understand why current targeted treatments, called EGFR-TKIs, sometimes stop working for these patients. Our team will look at genetic markers and signaling pathways to identify early signs of resistance. We are also exploring how a person's race, ethnicity, and genetic background might influence how well these treatments work. Ultimately, this work aims to develop new drug combinations to overcome treatment resistance, which could then be tested in future clinical trials.
Who could benefit from this research
Good fit: Patients with EGFR-mutant non-small cell lung cancer, particularly those of Latino or Asian descent, are the focus of this research.
Not a fit: Patients with other types of lung cancer or those whose cancer does not have EGFR mutations may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and personalized treatments for lung cancer, especially for Latino and Asian patients who often face unique challenges with current therapies.
How similar studies have performed: This research builds on existing knowledge about EGFR-mutant lung cancer and aims to develop novel therapeutic strategies to overcome treatment resistance.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Riess, Jonathan W — University of California at Davis
- Study coordinator: Riess, Jonathan W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.